The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Introduction: Limited data exists on the safety and efficacy of direct‐acting oral
anticoagulants (DOAC) use in morbidly obese patients with venous thromboembolism …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …

Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Background: Obesity is a real burden and its prevalence is constantly increasing. High body
weight is a risk factor for developing venous thromboembolism (VTE). Direct oral …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Background Direct oral anticoagulants (DOACs) are an increasingly popular treatment
option in atrial fibrillation (Afib), deep vein thrombosis (DVT), and pulmonary embolism (PE) …

Background Anticoagulation is an effective treatment in prevention of stroke in patients with
atrial fibrillation (AF). Direct anticoagulants (DOACs) have been favored over vitamin K …

Background Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main
cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this …